PSMA

Real-world results confirm benefit of PSMA therapy for prostate cancer

Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the landmark VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk profile of the therapy, […]

Read More

PSMA PETCT-targeted biopsy improves detection of clinically significant prostate cancer

PSMA PETCT-targeted biopsy detects more clinically significant prostate cancer than systematic biopsy alone in men whose MRI findings are negative or inconclusive yet have persistent clinical risk factors. According to new research published in the September issue of The Journal of Nuclear Medicine, combining the two biopsy approaches is even more effective, nearly doubling the […]

Read More